ALEXANDER LEE SCHMIDT
Engineering in Bethesda, MD
License number
Pennsylvania ET011281
Category
Engineers
Type
Engineer in Training
Address
Address
2
Bethesda, MD 20816
Pennsylvania
Pennsylvania
Professional information
Attenuated Human-Bovine Chimeric Parainfluenza Virus (Piv) Vaccines
US Patent:
7622123, Nov 24, 2009
Filed:
Nov 4, 2004
Appl. No.:
10/982223
Inventors:
Mario H. Skiadopoulos - Potomac MD, US
Peter L. Collins - Kensington MD, US
Brian R. Murphy - Bethesda MD, US
Alexander C. Schmidt - Bethesda MD, US
Peter L. Collins - Kensington MD, US
Brian R. Murphy - Bethesda MD, US
Alexander C. Schmidt - Bethesda MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/155
US Classification:
4241991, 4242111
Abstract:
Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
Attenuated Parainfluenza Virus (Piv) Vaccines
US Patent:
2008009, Apr 24, 2008
Filed:
Apr 17, 2007
Appl. No.:
11/785364
Inventors:
Brian Murphy - Bethesda MD, US
Peter Collins - Bethesda MD, US
Anna Durbin - Takoma Park MD, US
Mario Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US
Alexander Schmidt - Bethesda MD, US
Jane Bailly - Sunnyvale CA, US
Peter Collins - Bethesda MD, US
Anna Durbin - Takoma Park MD, US
Mario Skiadopoulos - Potomac MD, US
Tao Tao - Bethesda MD, US
Alexander Schmidt - Bethesda MD, US
Jane Bailly - Sunnyvale CA, US
Assignee:
The Government of the US, Represented by the Secretary, Dept. of Health & Human Services - Rockville MD
International Classification:
C12N 7/00, C07H 21/04
US Classification:
435235100, 536023720
Abstract:
The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.
Human Parainfluenza Viruses Having Separated P And C Genes
US Patent:
2010033, Dec 30, 2010
Filed:
May 8, 2008
Appl. No.:
12/599095
Inventors:
Peter L. Collins - Silver Spring MD, US
Brian R. Murphy - Bethesda MD, US
Mario H. Skiadopoulos - Potomac MD, US
Emmalene J. Bartlett - Chevy Chase MD, US
Alexander C. Schmidt - Bethesda MD, US
Ann-Marie M. Cruz - Bethesda MD, US
Brian R. Murphy - Bethesda MD, US
Mario H. Skiadopoulos - Potomac MD, US
Emmalene J. Bartlett - Chevy Chase MD, US
Alexander C. Schmidt - Bethesda MD, US
Ann-Marie M. Cruz - Bethesda MD, US
International Classification:
A61K 39/155, C12N 7/01, C07H 21/04, C12N 7/04, A61P 37/04, A61P 31/14
US Classification:
4242111, 4352351, 536 2372, 435236
Abstract:
The invention provides self replicating infectious recombinant paramyxoviruses where the P and C genes are separated rated. The recombinant paramyxoviruses preferably have one or more attenuating mutations and/or at least one temperature sensitive mutation and one non-temperature sensitive mutation. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a C protein and a separate monocistronic polynucleotide encoding a P protein. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.